Aptevo Therapeutics Statistics
Share Statistics
Aptevo Therapeutics has 8.11M
shares outstanding. The number of shares has increased by -64.26%
in one year.
| Shares Outstanding | 8.11M |
| Shares Change (YoY) | -64.26% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 15.37% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 452.28K, so 8.15% of the outstanding
shares have been sold short.
| Short Interest | 452.28K |
| Short % of Shares Out | 8.15% |
| Short % of Float | 8.15% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.05 and the forward
PE ratio is -0.03.
Aptevo Therapeutics's PEG ratio is
0.
| PE Ratio | -0.05 |
| Forward PE | -0.03 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/FCF Ratio | -0.05 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aptevo Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72,
with a Debt / Equity ratio of 0.97.
| Current Ratio | 1.72 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.97 |
| Debt / EBITDA | -0.19 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-652,162.16 |
| Employee Count | 37 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 6.06, so Aptevo Therapeutics's
price volatility has been higher than the market average.
| Beta | 6.06 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 6.09 |
| Relative Strength Index (RSI) | 27.68 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.6M |
| Net Income | -24.13M |
| EBITDA | -23.78M |
| EBIT | -24.13M |
| Earnings Per Share (EPS) | -84.67 |
Full Income StatementBalance Sheet
The company has 8.71M in cash and 4.63M in
debt, giving a net cash position of 4.08M.
| Cash & Cash Equivalents | 8.71M |
| Total Debt | 4.63M |
| Net Cash | 4.08M |
| Retained Earnings | -247.58M |
| Total Assets | 8.34M |
| Working Capital | -1.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -23.79M
and capital expenditures 0, giving a free cash flow of -23.79M.
| Operating Cash Flow | -23.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -23.79M |
| FCF Per Share | -86.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
